eClinical Solutions Market

eClinical Solutions Market by Product (CDMS, eCOA, CTMS, RTSM, ETMF, Analytics, Safety), Delivery (Web-hosted, Licensed Enterprise, Cloud-based), End User (Pharma, Hospitals, CROs), Clinical Trial Phases (Phase I, II) & Region - Global Forecast to 2027

Report Code: HIT 2208 Jan, 2023, by marketsandmarkets.com

The global eClinical solutions market in terms of revenue was estimated to be worth $9.6 billion in 2022 and is poised to reach $17.9 billion by 2027, growing at a CAGR of 13.3% from 2022 to 2027. Market growth is primarily driven by the rising operational costs and regulatory requirements associated with clinical research studies; the growing adoption of novel software solutions in clinical research; favourable government support and funding for clinical trials; the rising need for improved data standardization; and the increasing R&D expenditure on drug development by pharma-biotech companies. However, factors such as high implementation costs associated with eClinical solutions, a shortage of skilled professionals, and limited awareness among researchers are expected to restrain the market growth to a certain extent.

Attractive Opportunities in eClinical solutions Market

eClinical Solutions Market

To know about the assumptions considered for the study, Request for Free Sample Report

eClinical Solutions Market Dynamics

Driver: Growing adoption of novel software solutions in clinical research

Patient recruitment and retention are major operational challenges for most researchers during clinical research studies. The shortage of real-time access to research data and manual data generation for protocol matrices often results in extended timelines and increased research expenditures associated with clinical trials. This may affect all phases, particularly research planning, data capture, data management, regulatory submission and reporting, and data analysis, resulting in delayed market entry of successful drug candidates. Therefore, researchers increasingly prefer innovative eClinical solutions that offer improved efficiency of clinical trials, enhance site performance, streamline research workload, and have higher cost efficiency than conventional methodologies. These software solutions allow pharmaceutical companies and independent researchers to compare the operating characteristics of the software design options; model, forecast, and track clinical trial enrollment; and identify the procedural bottlenecks associated with clinical trials. The procedural and operational benefits offered by eClinical solutions are resulting in significant growth in the adoption of these solutions among CROs, independent researchers, and pharmaceutical, medical device, and biotechnology companies for their clinical research programs.

Restraint: High implementation costs associated with eClinical solutions

eClinical solutions help researchers efficiently organize, standardize, and manage their clinical research data and metadata during their research lifecycle. Several integrated eClinical solutions (such as CTMS and CDMS) provide end-to-end solutions to clinical researchers for all clinical trial processes. However, these software solutions are expensive and priced at a premium. The installation and maintenance of eClinical solutions cost approximately USD 2 million, with additional costs for technical assistance for cloud-based solutions. The high costs associated with advanced eClinical software solutions are expected to restrain optimal adoption among price-sensitive and small-sized end users, including pharma-biotech companies, independent researchers, and CROs.

Opportunity: Growing outsourcing of clinical trial processes to CROs

Traditionally, pharmaceutical and biotechnology product manufacturing companies were the primary end users of clinical trial products and software. However, with the increasing availability of public-private research funding and strengthening private R&D infrastructure across major markets, several CROs and research-based companies are offering specific research services to various end users. Pharmaceutical and biotechnology companies are increasingly outsourcing less important clinical research activities to these CROs and research companies. Although the pharmaceutical industry is still engaging healthcare providers [such as academic medical centres (AMCs), academic universities, hospitals, and research centers] for clinical trial capabilities, the extent of process outsourcing of clinical trials to AMCs has significantly decreased in the past decade owing to the growing preference for CROs. Rising outsourcing of activities to CROs, coupled with the growing number of CROs across emerging markets, is expected to provide new revenue growth opportunities for market players in the eClinical Solutions industry in the coming years.

Challenge: Limited adoption in emerging countries due to budgetary constraints

The adoption of eClinical solutions in emerging countries is currently very low as technology usage and awareness are restricted. However, there is higher utilisation in parts of the Asia Pacific compared to countries in the Middle East and Africa. The healthcare IT industry experiences low adoption in several developing and underdeveloped markets due to the high costs involved in implementing, maintaining, and upgrading IT solutions. Overcoming such financial constraints in emerging economies is a major challenge for healthcare organizations, as obtaining budgetary approvals for advanced HCIT solutions is challenging. Smaller healthcare organisations struggle to implement internet connectivity for medical devices due to technical difficulties in implementing multiple networks in healthcare setups, poor wireless connectivity, and an enhanced need to instal security layers to avoid data breaches. Poor in-house skilled personnel and insufficient IT infrastructure also contribute to a lower rate of eClinical software solution implementation.

The product segment of the eClinical Solutions market was dominated by EDC and CDMS.

Based on product, the market is segmented into electronic data capture (EDC) and clinical data management systems (CDMS), clinical trial management systems (CTMS), clinical analytics platforms, randomization and trial supply management (RTSM) solutions, clinical data integration platforms, electronic clinical outcome assessment (eCOA) solutions, safety solutions, electronic trial master file (eTMF) systems, eConsent (electronic consent) solutions, regulatory information management systems (RIMS), and other eClinical solutions. The electronic data capture (EDC) and clinical data management systems (CDMS) segment dominated the global eClinical solutions market in 2021 with a share of 16.9%. Factors such as the increasing need to reduce the time and costs associated with clinical trials, the growing demand for data standardisation to meet regulatory requirements, and pharmaceutical companies increasing R&D expenditure are driving the growth of the EDC and CDMS solutions market.

In the eClinical Solutions market, cloud-based delivery models are expected to grow the most.

Based on delivery mode, the market is segmented into web-hosted (on-demand), licenced enterprise (on-premises), and cloud-based (SaaS) models. The cloud-based eClinical solutions segment is estimated to register the highest CAGR of 17.8% during the forecast period. The ease of integration, fast deployment, and flexible scalability with a fixed monthly fee offered by cloud-based models are expected to drive the demand for these solutions during the forecast period.

Phase III clinical trials held the largest share of the eClinical solutions market in 2021.

Based on the clinical trial phase, the market is segmented into phases I, II, III, and IV. The significant demand for eClinical solutions in phase III clinical trials is mainly due to the involvement of a large patient sample population, the globalisation of clinical trials, and the rising need to increase the efficiency of clinical trials.

Contract research organizations (CROs) will experience the most rapid growth in the eClinical Solutions market.

Based on end users, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, consultancy service companies, medical device manufacturers, hospitals, and academic and research institutes. Contract research organizations (CROs) form the fastest-growing segment of the global eClinical solutions market, registering the highest CAGR of 15.5% during the forecast period. The increasing trend of outsourcing clinical trial activities to CROs is expected to drive market growth for this segment in the coming years.

The eClinical Solutions market was dominated by North America.

In 2021, North America held the largest share of the eClinical Solutions market. The large regional share can be attributed to factors such as increasing government grants to support clinical trials, the large number of ongoing clinical trials, continuous product development by eClinical Solution vendors, the growing number of partnerships for drug development projects, and the high prevalence of lifestyle diseases coupled with a growing senior population.

eClinical Solutions Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Among the prominent players in the eClinical Solutions market are Oracle Corporation (US), Parexel International Corporation (US), Dassault Systèmes (France), Clario (US), Datatrak International (US), Signant Health (US), 4G Clinical (US), MaxisIT (US), IBM Watson Health (US), eClinical Solutions LLC (US), Veeva Systems (US), Research Manager (US), Saama Technologies, LLC (US), Mednet (US), Anju Software, Inc (US), Medrio, Inc. (US), Castor (US), Clinipace (US), ArisGlobal (US), Quretec Ltd. (Estonia), OpenClinica, LLC (US), Advarra (US), RealTime Software Solutions, LLC (US), YPrime LLC. (US) and Vial (US).

eClinical Solutions Market Report Scope

Report Metric

Details

Market Revenue in 2022

$9.6 billion

Estimated Value by 2027

$17.9 billion

Growth Rate

Poised to grow at a CAGR of 13.3%

Forecast units

Value (USD USD Billion)

Segments covered

By Product, By Delivery Mode, By Clinical Trial Phases, By End User & By Region

Geographies covered

North America, Europe, Asia Pacific, Rest of the World

Companies covered

Oracle Corporation (US), Clario (US), IBM Watson Health (US), eClinical Solutions LLC (US), Veeva Systems (US), Research Manager (US), Among others. (Total 25 companies)

This report categorizes the eClinical solutions market into the following segments:

By Product

  • Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS)
  • Clinical Trial Management Systems (CTMS)
  • Clinical Analytics Platforms
  • Randomization & Trial Supply Management Systems (RTSM)
  • Clinical Data Integration Platforms
  • Electronic Clinical Outcome Assessment Solutions (eCOA)
  • Safety Solutions
  • Electronic Trial Master File (eTMF) Systems
  • Electronic Consent Solutions (eConsent)
  • Regulatory Information Management Systems (RIMS)
  • Other eClinical Solutions

By Delivery Mode

  • Web-hosted Models
  • Licensed Enterprise Models
  • Cloud-based Models

By Clinical Trial Phases

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Research Organizations
  • Consultancy Service Companies
  • Medical Device Manufacturers
  • Hospitals
  • Academic & Research Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of APAC (RoAPAC)
  • RoW

Recent Developments

  • In November 2022, Medidata (US) introduced Rave Companion, the first scalable solution, to automate the entry of EHR data into Rave EDC. Several potential errors are avoided by clinical trial sites and data managers owing to the modernization of the EDC user experience by Rave Companion.
  • In July 2022, Oracle Corporation (US) partnered with Microsoft (US) to give Azure customers direct and streamlined access to Oracle databases on Oracle Cloud Infrastructure (OCI).
  • In June 2022, Clario (US) partnered with IDDI (Belgium) to distribute software to its clientele through its Randomized Trial Supply Management (RTSM) Software as a Service business. IDDI will be able to launch clinical studies efficiently and affordably in various markets with the use of Clario RTSM.
  • In April 2021, Datatrak International (US) launched Datatrak Direct, an all-in-one iOS and Android data collection app for ePRO, eCOA, and eConsent.
  • In February 2021, Parexel (US) partnered with NeoGenomics (US) to improve the application of precision medicine in oncology clinical trials to optimise the patient selection process.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 45)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKET SEGMENTATION
           1.2.3 GEOGRAPHIES COVERED
           1.2.4 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED 
    1.4 LIMITATIONS 
    1.5 MAJOR MARKET STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 51)
    2.1 RESEARCH APPROACH 
    2.2 RESEARCH METHODOLOGY STEPS 
          FIGURE 1 ECLINICAL SOLUTIONS MARKET: RESEARCH METHODOLOGY
    2.3 RESEARCH METHODOLOGY DESIGN 
          FIGURE 2 ECLINICAL SOLUTIONS MARKET: RESEARCH DESIGN
           2.3.1 SECONDARY DATA
                    2.3.1.1 Secondary sources
           2.3.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.3.2.1 Insights from primary experts
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY,  DESIGNATION, AND REGION
    2.4 MARKET SIZE ESTIMATION 
          FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
          FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
          FIGURE 8 REVENUE ANALYSIS OF TOP 3 PUBLIC COMPANIES IN ECLINICAL  SOLUTIONS MARKET (2021)
          FIGURE 9 BOTTOM-UP APPROACH
          FIGURE 10 ECLINICAL SOLUTIONS MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
          FIGURE 11 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
          FIGURE 12 TOP-DOWN APPROACH
    2.5 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 13 DATA TRIANGULATION METHODOLOGY
    2.6 STUDY ASSUMPTIONS 
    2.7 LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS
    2.8 RISK ASSESSMENT 
          TABLE 1 ECLINICAL SOLUTIONS MARKET: RISK ASSESSMENT
    2.9 RECESSION IMPACT ON ECLINICAL SOLUTIONS MARKET 
          TABLE 2 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH)
          TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 67)
    FIGURE 14 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2022 VS. 2027 (USD MILLION)
    FIGURE 16 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2022 VS. 2027 (USD MILLION)
    FIGURE 17 ECLINICAL SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 18 ECLINICAL SOLUTIONS MARKET: REGIONS COVERED (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 71)
    4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW 
          FIGURE 19 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
    4.2 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE & COUNTRY (2021) 
          FIGURE 20 WEB-HOSTED DELIVERY MODEL ACCOUNTED FOR LARGEST SHARE IN 2021
    4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA IS EXPECTED TO ACCOUNT FOR HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 73)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 ECLINICAL SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising operational costs and regulatory requirements associated with clinical research studies
                    5.2.1.2 Growing adoption of novel software solutions in clinical research
                    5.2.1.3 Favorable government support and funding for clinical trials
                    5.2.1.4 Rising need for improved data standardization
                    5.2.1.5 Increasing R&D expenditure on drug development by pharma-biotech companies
           5.2.2 RESTRAINTS
                    5.2.2.1 High implementation costs associated with eClinical solutions
                    5.2.2.2 Shortage of skilled professionals
                    5.2.2.3 Limited awareness among researchers
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing clinical trials in emerging countries
                    5.2.3.2 Growing outsourcing of clinical trial processes to CROs
                    5.2.3.3 Gradual shift from manual data interpretation to real-time data analysis
           5.2.4 CHALLENGES
                    5.2.4.1 Limited adoption in emerging countries due to budgetary constraints
                    5.2.4.2 Concerns regarding software reliability
                    5.2.4.3 Issues associated with patient privacy
    5.3 ECLINICAL SOLUTIONS MARKET: ECOSYSTEM ANALYSIS 
          FIGURE 23 ECOSYSTEM ANALYSIS
    5.4 CASE STUDIES 
           5.4.1 YORK TEACHING HOSPITAL EXPEDITES DATA CAPTURE PROCESSING DURING PHASE III CLINICAL STUDY
           5.4.2 LSHTM AND MENAFRICAR INCORPORATE DATA CAPTURE SOFTWARE TO STUDY MENINGOCOCCAL CARRIAGE IN AFRICA
           5.4.3 CLINICAL TRIALS GROUP AT UCL UTILIZES EDC SYSTEM TO CAPTURE AND VERIFY PATIENT FEEDBACK
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 24 ECLINICAL SOLUTIONS MARKET: VALUE CHAIN ANALYSIS
    5.6 PORTER'S FIVE FORCES ANALYSIS 
          TABLE 5 HIGH CAPITAL INVESTMENTS TO RESTRICT ENTRY OF NEW PLAYERS
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 THREAT OF SUBSTITUTES
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 BARGAINING POWER OF SUPPLIERS
           5.6.5 INTENSITY OF COMPETITIVE RIVALRY
    5.7 REGULATORY LANDSCAPE 
           5.7.1 NORTH AMERICA
           5.7.2 EUROPE
           5.7.3 ASIA PACIFIC
           5.7.4 MIDDLE EAST & AFRICA
           5.7.5 LATIN AMERICA
    5.8 TECHNOLOGY ANALYSIS 
          TABLE 6 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS
    5.9 INDUSTRY TRENDS 
           5.9.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRAILS
           5.9.2 GROWING ADOPTION OF TELEMEDICINE
           5.9.3 IMPACT OF BIG DATA ON HEALTHCARE
    5.10 PRICING ANALYSIS 
           5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS
                     TABLE 7 AVERAGE SELLING PRICE OF ECLINICAL SOLUTIONS, BY LICENSE
    5.11 KEY CONFERENCES AND EVENTS FROM 2022−2023 
           TABLE 8 ECLINICAL SOLUTIONS MARKET: LIST OF CONFERENCES AND EVENTS FROM 2022−2023
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS
           TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS
           5.12.1 BUYING CRITERIA
                     FIGURE 26 KEY BUYING CRITERIA FOR END USERS
                     TABLE 10 KEY BUYING CRITERIA FOR END USERS
 
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT (Page No. - 91)
    6.1 INTRODUCTION 
          TABLE 11 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
          TABLE 12 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS 
           6.2.1 UTILIZATION OF COST-EFFECTIVE ECLINICAL SOLUTIONS INTEGRATED WITH EDC & CDM SYSTEMS TO DRIVE MARKET
                    TABLE 13 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 14 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 15 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 16 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 18 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 20 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS 
           6.3.1 ABILITY TO BE DEPLOYED AS A SECURE WEB APPLICATION TO DRIVE UPTAKE
                    TABLE 21 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS,  BY REGION, 2016–2019 (USD MILLION)
                    TABLE 22 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS,  BY REGION, 2020–2027 (USD MILLION)
                    TABLE 23 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 24 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 25 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 26 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 28 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 CLINICAL ANALYTICS PLATFORMS 
           6.4.1 ABILITY TO AUTOMATE CLINICAL DEVELOPMENT ACTIVITIES TO DRIVE MARKET
                    TABLE 29 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION,  2016–2019 (USD MILLION)
                    TABLE 30 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 31 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 32 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 33 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 34 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS,  BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS 
           6.5.1 EFFECTIVE MANAGEMENT OF INVENTORY MONITORING AND RANDOMIZED PATIENT POOLS TO DRIVE ADOPTION
                    TABLE 37 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 38 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 39 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 40 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 41 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 42 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 CLINICAL DATA INTEGRATION PLATFORMS 
           6.6.1 ABILITY TO OPTIMIZE SECURE EXCHANGE OF EHR ON A USER-FRIENDLY GUI TO FUEL MARKET
                    TABLE 45 ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS,  BY REGION, 2016–2019 (USD MILLION)
                    TABLE 46 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL INTEGRATION PLATFORMS,  BY REGION, 2020–2027 (USD MILLION)
                    TABLE 47 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 48 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 49 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 50 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 52 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS 
           6.7.1 INCREASING ADOPTION OF EPRO SOLUTIONS AND EDIARIES AMONG PHARMA COMPANIES TO DRIVE UPTAKE
                    TABLE 53 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 54 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 55 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 56 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 57 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 58 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 60 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.8 SAFETY SOLUTIONS 
           6.8.1 ABILITY TO STREAMLINE SAFETY PROCESSING PROCESSES DURING CLINICAL TRIALS TO SUPPORT MARKET GROWTH
                    TABLE 61 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION,  2016–2019 (USD MILLION)
                    TABLE 62 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 63 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 64 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 65 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 66 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 67 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS 
           6.9.1 RAPID SEARCH AND RETRIEVAL OF CLINICAL TRIAL DOCUMENTS WITH ETMF TO FUEL MARKET
                    TABLE 69 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS,  BY REGION, 2016–2019 (USD MILLION)
                    TABLE 70 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS,  BY REGION, 2020–2027 (USD MILLION)
                    TABLE 71 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 72 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 73 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 74 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 76 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.10 ELECTRONIC CONSENT SOLUTIONS 
           6.10.1 ABILITY TO ENSURE ADHERENCE TO ICF REGULATIONS TO INCREASE ADOPTION
                     TABLE 77 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2016–2019 (USD MILLION)
                     TABLE 78 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 79 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 80 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                     TABLE 81 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS,  BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 82 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS,  BY COUNTRY, 2020–2027 (USD MILLION)
                     TABLE 83 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 84 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.11 REGULATORY INFORMATION MANAGEMENT SYSTEMS 
           6.11.1 ABILITY TO ASSIST RESEARCHERS IN CENTRALIZING REGULATORY INFORMATION FOR OPTIMAL STANDARDIZATION TO DRIVE MARKET
                     TABLE 85 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2016–2019 (USD MILLION)
                     TABLE 86 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2020–2027 (USD MILLION)
                     TABLE 87 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 88 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                     TABLE 89 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 90 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
                     TABLE 91 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016–2019 (USD MILLION)
                     TABLE 92 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.12 OTHER ECLINICAL SOLUTIONS 
           TABLE 93 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD MILLION)
           TABLE 94 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION)
           TABLE 95 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2016–2019 (USD MILLION)
           TABLE 96 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           TABLE 97 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2016–2019 (USD MILLION)
           TABLE 98 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           TABLE 99 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2016–2019 (USD MILLION)
           TABLE 100 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
 
7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE (Page No. - 128)
    7.1 INTRODUCTION 
          TABLE 101 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
          TABLE 102 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
    7.2 WEB-HOSTED MODELS 
           7.2.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET
                    TABLE 103 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION,  2016–2019 (USD MILLION)
                    TABLE 104 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 105 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 106 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTEL MODELS,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 107 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 108 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 109 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 110 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 LICENSED ENTERPRISE MODELS 
           7.3.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
                    TABLE 111 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 112 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 113 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 114 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 115 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 116 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 117 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 118 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS,  BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 CLOUD-BASED SOLUTIONS 
           7.4.1 REMOTE CENTRALIZED ACCESS WITH REAL-TIME ANALYSIS TO DRIVE MARKET
                    TABLE 119 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION,  2016–2019 (USD MILLION)
                    TABLE 120 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 121 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 122 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 123 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 124 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 125 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 126 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS,  BY COUNTRY, 2020–2027 (USD MILLION)
 
8 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE (Page No. - 140)
    8.1 INTRODUCTION 
          TABLE 127 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016–2019 (USD MILLION)
          TABLE 128 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020–2027 (USD MILLION)
    8.2 PHASE I CLINICAL TRIALS 
           8.2.1 ADOPTION OF EDC & CDM SYSTEMS IN PHASE I STUDIES TO DRIVE MARKET
                    TABLE 129 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 130 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 131 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 132 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 133 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 134 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 135 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 136 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY,  2020–2027 (USD MILLION)
    8.3 PHASE II CLINICAL TRIALS 
           8.3.1 UTILIZATION OF ECLINICAL SOLUTIONS IN STREAMLINING PHASE II TRIALS TO BOOST MARKET
                    TABLE 137 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 138 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 139 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 140 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 141 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 142 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 143 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 144 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY,  2020–2027 (USD MILLION)
    8.4 PHASE III CLINICAL TRIALS 
           8.4.1 INVOLVEMENT OF A LARGE PATIENT POPULATION TO DRIVE MARKET
                    TABLE 145 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 146 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 147 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 148 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 149 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 150 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 151 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 152 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY,  2020–2027 (USD MILLION)
    8.5 PHASE IV CLINICAL TRIALS 
           8.5.1 RISING DEMAND FOR POST-MARKETING SURVEILLANCE TO SUPPORT MARKET GROWTH
                    TABLE 153 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 154 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 155 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 156 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 157 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 158 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 159 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 160 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY,  2020–2027 (USD MILLION)
 
9 ECLINICAL SOLUTIONS MARKET, BY END USER (Page No. - 155)
    9.1 INTRODUCTION 
          TABLE 161 ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
          TABLE 162 ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 
           9.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
                    TABLE 163 ECLINICAL SOLUTIONS MARKET SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 164 ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 165 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 166 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 167 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 168 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 169 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 170 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS 
           9.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS  BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
                    TABLE 171 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,  BY REGION, 2016–2019 (USD MILLION)
                    TABLE 172 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 173 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 174 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 175 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 176 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 177 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 178 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 CONSULTANCY SERVICE COMPANIES 
           9.4.1 GROWING COLLABORATIONS FOR CDM BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET
                    TABLE 179 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 180 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 181 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 182 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 183 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 184 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 185 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 186 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.5 MEDICAL DEVICE MANUFACTURERS 
           9.5.1 UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL MARKET
                    TABLE 187 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 188 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 189 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 190 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 191 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 192 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 193 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 194 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.6 HOSPITALS 
           9.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET
                    TABLE 195 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION,  2016–2019 (USD MILLION)
                    TABLE 196 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 197 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 198 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 199 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 200 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 201 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY,  2016–2019 (USD MILLION)
                    TABLE 202 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY,  2020–2027 (USD MILLION)
    9.7 ACADEMIC & RESEARCH INSTITUTES 
           9.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
                    TABLE 203 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 204 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 205 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 206 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 207 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 208 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 209 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2019 (USD MILLION)
                    TABLE 210 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 ECLINICAL SOLUTIONS MARKET, BY REGION (Page No. - 176)
     10.1 INTRODUCTION 
             TABLE 211 ECLINICAL SOLUTIONS MARKET, BY REGION, 2016–2019 (USD MILLION)
             TABLE 212 ECLINICAL SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 27 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SNAPSHOT
             TABLE 213 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2016–2019 (USD MILLION)
             TABLE 214 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
             TABLE 215 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2016–2019 (USD MILLION)
             TABLE 216 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
             TABLE 217 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
             TABLE 218 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
             TABLE 219 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
             TABLE 220 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
             TABLE 221 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
             TABLE 222 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER,  2020–2027 (USD MILLION)
             10.2.1 NORTH AMERICA: RECESSION IMPACT
             10.2.2 US
                        10.2.2.1 Rising government funding for pharmaceutical R&D  to drive market
                                      FIGURE 28 DISTRIBUTION OF R&D COMPANIES BY COUNTRY/REGION (2021 VS. 2022)
                                      TABLE 223 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 224 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 225 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 226 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                                      TABLE 227 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 228 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 229 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 230 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
                                      TABLE 231 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 232 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 233 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                                      TABLE 234 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                                      TABLE 235 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 236 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 237 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 238 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             TABLE 239 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
             TABLE 240 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 241 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
             TABLE 242 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 243 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
             TABLE 244 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
             TABLE 245 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
             TABLE 246 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
             TABLE 247 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
             TABLE 248 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.1 EUROPE: RECESSION IMPACT
             10.3.2 GERMANY
                        10.3.2.1 High number of sponsored clinical trials to drive uptake of eClinical solutions
                                      TABLE 249 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 250 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 251 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                                      TABLE 252 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                                      TABLE 253 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 254 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 255 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
                                      TABLE 256 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
                                      TABLE 257 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 258 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 259 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 260 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 261 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 262 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 263 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 264 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Growing R&D pipeline for oncology trials to drive market
                                      TABLE 265 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 266 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 267 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                                      TABLE 268 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                                      TABLE 269 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 270 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 271 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 272 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
                                      TABLE 273 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
                                      TABLE 274 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 275 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 276 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 277 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 278 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 279 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 280 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 281 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Established network of research centers to propel market
                                      TABLE 282 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 283 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 284 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 285 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 286 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 287 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 288 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
                                      TABLE 289 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 290 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2016–2019 (USD MILLION)
                        TABLE 291 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                        TABLE 292 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                        TABLE 293 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                        TABLE 294 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                        TABLE 295 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                        TABLE 296 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
                        TABLE 297 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER,  2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 29 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET SNAPSHOT
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 298 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
                        TABLE 299 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 300 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                        TABLE 301 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 302 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                        TABLE 303 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                        TABLE 304 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                        TABLE 305 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                        TABLE 306 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
                        TABLE 307 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,  2020–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market
                                      TABLE 308 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 309 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 310 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                                      TABLE 311 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 312 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 313 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 314 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 315 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Established clinical trial infrastructure and biomedical research capabilities to support market growth
                                      TABLE 316 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 317 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 318 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 319 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 320 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 321 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 322 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 323 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Growing pharmaceutical industry to fuel uptake of eClinical solutions
                                      TABLE 324 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
                                      TABLE 325 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 326 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016–2019 (USD MILLION)
                                      TABLE 327 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020–2027 (USD MILLION)
                                      TABLE 328 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                                      TABLE 329 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                                      TABLE 330 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016–2019 (USD MILLION)
                                      TABLE 331 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 332 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2016–2019 (USD MILLION)
                        TABLE 333 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
                        TABLE 334 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
                        TABLE 335 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
                        TABLE 336 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
                        TABLE 337 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
                        TABLE 338 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
                        TABLE 339 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER,  2020–2027 (USD MILLION)
     10.5 REST OF THE WORLD 
             TABLE 340 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2016–2019 (USD MILLION)
             TABLE 341 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT,  2020–2027 (USD MILLION)
             TABLE 342 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2016–2019 (USD MILLION)
             TABLE 343 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE,  2020–2027 (USD MILLION)
             TABLE 344 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2016–2019 (USD MILLION)
             TABLE 345 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE,  2020–2027 (USD MILLION)
             TABLE 346 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER,  2016–2019 (USD MILLION)
             TABLE 347 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER,  2020–2027 (USD MILLION)
             10.5.1 REST OF THE WORLD: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 252)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 
             FIGURE 30 ECLINICAL SOLUTIONS MARKET: KEY PLAYERS
     11.4 MARKET RANKING ANALYSIS (2021) 
             FIGURE 31 ECLINICAL SOLUTIONS MARKET: COMPANY RANKS (2021)
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 32 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021)
     11.6 ECLINICAL SOLUTIONS MARKET: COMPETITIVE EVALUATION QUADRANT FOR SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 33 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT  FOR SMES (2021)
     11.7 COMPETITIVE BENCHMARKING 
            FIGURE 34 ECLINICAL SOLUTIONS MARKET: OVERALL FOOTPRINT OF 15 COMPANIES
            TABLE 348 ECLINICAL SOLUTIONS MARKET: COMPANY PRODUCT FOOTPRINT
            TABLE 349 ECLINICAL SOLUTIONS MARKET: END USER FOOTPRINT
            TABLE 350 ECLINICAL SOLUTIONS MARKET: COMPANY REGIONAL FOOTPRINT
     11.8 COMPETITIVE SITUATIONS AND TRENDS 
             11.8.1 PRODUCT AND SERVICE LAUNCHES
                        TABLE 351 PRODUCT AND SERVICE LAUNCHES (2019−2022)
             11.8.2 DEALS
                        TABLE 352 DEALS (2019−2022)
 
12 COMPANY PROFILES (Page No. - 265)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 ORACLE CORPORATION
                        TABLE 353 ORACLE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 35 ORACLE CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.2 DASSAULT SYSTÈMES
                        TABLE 354 DASSAULT SYSTÈMES: BUSINESS OVERVIEW
                        FIGURE 36 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2021)
             12.1.3 PAREXEL INTERNATIONAL CORPORATION
                        TABLE 355 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
             12.1.4 CLARIO
                        TABLE 356 CLARIO: BUSINESS OVERVIEW
             12.1.5 DATATRAK INT.
                        TABLE 357 DATATRAK INT.: BUSINESS OVERVIEW
                        FIGURE 37 DATATRAK INT.: COMPANY SNAPSHOT (2021)
             12.1.6 SIGNANT HEALTH (CRF HEALTH)
                        TABLE 358 SIGNANT HEALTH: BUSINESS OVERVIEW
             12.1.7 MAXISIT INC.
                        TABLE 359 MAXISIT INC.: BUSINESS OVERVIEW
             12.1.8 4G CLINICAL
                        TABLE 360 4G CLINICAL: BUSINESS OVERVIEW
             12.1.9 ECLINICAL SOLUTIONS LLC.
                        TABLE 361 ECLINICAL SOLUTIONS: BUSINESS OVERVIEW
             12.1.10 VEEVA SYSTEMS
                        TABLE 362 VEEVA SYSTEMS: BUSINESS OVERVIEW
                        FIGURE 38 VEEVA SYSTEMS: COMPANY SNAPSHOT (2021)
     12.2 OTHER PLAYERS 
             12.2.1 RESEARCHMANAGER
             12.2.2 SAAMA TECHNOLOGIES
             12.2.3 MEDNET
             12.2.4 ANJU SOFTWARE (PORTFOLIO COMPANY OF ABRY PARTNERS)
             12.2.5 MEDRIO, INC.
             12.2.6 CASTOR
             12.2.7 CLINIPACE
             12.2.8 IBM WATSON HEALTH
             12.2.9 ARISGLOBAL
             12.2.10 QURETEC LTD.
             12.2.11 OPENCLINICA, LLC.
             12.2.12 ADVARRA
             12.2.13 REALTIME SOFTWARE SOLUTIONS, LLC
             12.2.14 YPRIME LLC.
             12.2.15 VIAL
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 300)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 

This study involved four major activities in estimating the size of eClinical solutions market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Wall Street Journal; white papers; and annual reports, company house documents, investor presentations, and SEC filings of companies. World Health Organization (WHO), World Bank, Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, Fierce Biotech, Organization for Economic Co-operation and Development (OECD), Centers for Medicare and Medicaid Services (CMS), Office for National Statistics (ONS), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), World Bank, Eurostat, Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the eClinical solutions market. It was also used to obtain important information about key market players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the eClinical solutions market. The primary sources from the demand side included hospitals, CROS, consultancy service companies, pharmaceutical and biopharmaceutical companies as well as academic & research institutes. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Breakdown of Primary Interviews

eClinical Solutions Market Size

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales, marketing, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2021: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Both top-down and bottom-up approaches were used to estimate and validate the total size of eClinical solutions market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The total number of clinical trials globally was estimated through secondary sources
  • Phase wise total cost per clinical trial was estimated through primary and secondary sources
  • Phase-wise cost of data management per clinical trial was estimated from primary and secondary sources. The average spend on eClinical solutions was estimated
  • Applying the spend on eClinical solutions per clinical trial was used to estimate the total spend on eClinical solutions for the year 2021 to arrive at the total global market size
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the eClinical solutions market based on product, delivery mode, clinical trial phase, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the global eClinical solutions market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets concerning their growth trends, prospects, and contributions to the global eClinical solutions market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the global eClinical solutions market with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
  • To track and analyze competitive developments in the eClinical solutions market, such as product launches and product enhancements; agreements, partnerships, and collaborations; as well as mergers and acquisitions
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product/service strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies in the eClinical solutions market

Contract Research Organizations (CROs) Market Segmentation by Clinical Trial Phase

  • Contract research organizations (CROs) market segmentation by clinical trial phase (including Phase I, Phase II, Phase III, and Phase IV clinical trials)

Company Information

  • Detailed analysis and profiling of additional market players (up to five)
Report Code
HIT 2208
Published ON
Jan, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the eClinical Solutions Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback